Cytosolic phospholipase a2 is required for fexofenadine′s therapeutic effects against inflammatory bowel disease in mice

Abstract

Inflammatory Bowel Disease (IBD) is an autoimmune condition with complicated pathology and diverse clinical signs. TNFα is believed to play a crucial role in the pathogenesis of IBD. We recently identified fexofenadine, a well‐known antagonist of histamine H1 receptor, as a novel inhibitor of TNFα signaling. Additionally, cytosolic phospholipase A2 (cPLA2) was isolated as a binding target of fexofenadine, and fexofenadine‐mediated anti‐TNF activity relied on cPLA2 in vitro. The objective of this study is to determine whether fexofenadine is therapeutic against chemically‐induced murine IBD model and whether cPLA2 and/or histamine H1 receptor is important for fexofenadine’s anti‐inflammatory activity in vivo by leveraging various genetically modified mice and chemically induced murine IBD models. Both dextran sulfate sodium‐ and 2, 4, 6‐trinitrobenzene sulfonic acid‐induced murine IBD models revealed that orally delivered fexofenadine was therapeutic against IBD, evidenced by mitigated clinical symptoms, decreased secretions of the proinflammatory cytokine IL‐6 and IL‐1β, lowered intestinal inflammation, and reduced p‐p65 and p‐IĸBα. Intriguingly, Fexofenadine‐mediated protective effects against IBD were lost in cPLA2 deficient mice but not in histamine H1 receptor‐deficient mice. Collectively, these findings demonstrate the therapeutic effects of over‐the‐counter drug Fexofenadine in treating DSSinduced IBD murine and provide first in vivo evidence showing that cPLA2 is required for fexofenadine’s therapeutic effects in murine IBD model and probably other inflammatory and autoimmune diseases as well.